1 not yet recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Relapsed or Refractory Acute Myeloid Leukemia: new trials by email Literature Review of Relapsed or Refractory Acute Myeloid Leukemia trials Research Report on Relapsed or Refractory Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia venetoclax, chidamide, and chiglitazar sodium (VCC) - Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-11-11 | 2026-08-24 |
| S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 80 | 2026-10-20 | 2026-09-03 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Mitoxantrone liposome, Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Hui Zeng | 70 | 2022-07-21 | 2022-08-30 |
Leukemia, Myeloid, Acute (3) · Recurrence (3)
Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
venetoclax (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1)
Hui Zeng (1) · Servier (1) · The First Affiliated Hospital of Xiamen University (1)
China (2)
Bing Xu (1) · Hui Zeng, M.D (1)
2025 (1)